Nektar Therapeutics (NASDAQ:NKTR) Director Jeffrey Robert Ajer sold 3,250 shares of the firm’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $17.25, for a total transaction of $56,062.50. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at approximately $448,068.75. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Jeffrey Robert Ajer also recently made the following trade(s):
- On Monday, September 21st, Jeffrey Robert Ajer sold 2,250 shares of Nektar Therapeutics stock. The shares were sold at an average price of $19.74, for a total transaction of $44,415.00.
NASDAQ NKTR opened at $16.59 on Thursday. The company has a 50 day simple moving average of $19.16 and a 200-day simple moving average of $20.49. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of -6.83 and a beta of 1.77. Nektar Therapeutics has a 52-week low of $13.63 and a 52-week high of $28.60.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.24. The business had revenue of $48.85 million during the quarter, compared to analyst estimates of $22.76 million. Nektar Therapeutics had a negative net margin of 264.38% and a negative return on equity of 28.23%. The firm’s revenue was up 109.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.63) earnings per share. As a group, equities research analysts predict that Nektar Therapeutics will post -2.62 EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Cfra lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. started coverage on shares of Nektar Therapeutics in a research report on Monday, September 14th. They set a “neutral” rating and a $26.00 price objective for the company. BidaskClub raised shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 17th. SVB Leerink reduced their price objective on shares of Nektar Therapeutics from $18.00 to $17.00 and set a “market perform” rating for the company in a research note on Friday, August 14th. Finally, Oppenheimer reaffirmed a “hold” rating and set a $25.00 price objective on shares of Nektar Therapeutics in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.50.
A number of institutional investors and hedge funds have recently modified their holdings of NKTR. State Street Corp raised its position in Nektar Therapeutics by 1.8% during the first quarter. State Street Corp now owns 4,631,555 shares of the biopharmaceutical company’s stock valued at $82,673,000 after acquiring an additional 81,450 shares in the last quarter. Victory Capital Management Inc. raised its position in Nektar Therapeutics by 108.0% during the first quarter. Victory Capital Management Inc. now owns 46,487 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 24,138 shares in the last quarter. Flagship Harbor Advisors LLC raised its position in Nektar Therapeutics by 47.8% during the first quarter. Flagship Harbor Advisors LLC now owns 7,070 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 2,285 shares in the last quarter. US Bancorp DE raised its position in Nektar Therapeutics by 0.6% during the first quarter. US Bancorp DE now owns 88,121 shares of the biopharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 507 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Nektar Therapeutics during the first quarter valued at approximately $201,000. 96.43% of the stock is currently owned by hedge funds and other institutional investors.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: What does EPS mean?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.